Drug Trial Radar · NCT02305797
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Last checked: Nov 19, 2026Latest source record: Sep 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
495
Actual
Start
Jan 2015
Primary completion
May 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Edgemont Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) and confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0). Efficacy will be measured by a statistically significant greater mean reduction from baseline compared to endpoint in anxiety symptoms as measured by the total score of the clinician-rated Hamilton Rating Scale for Anxiety (HAM-A) for the EDG004 treatment group compared to placebo.
Conditions
- Generalized Anxiety Disorder (GAD)
Interventions
Extended-release lorazepamDrug
Extended-release lorazepam capsules
PlaceboDrug
Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42)Time frame: Day 42 (Visit 7)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Multiple Investigational Sites
Multiple Locations, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.